Evidence map›Paper›PMID 40032932›Full record

ArticleScientific reports2025

Synbiotics as a novel therapeutic approach for hyperphosphatemia and hyperparathyroidism in chronic kidney disease rats.

Weerapat Anegkamol, Wirin Bowonsomsarit, Mana Taweevisit, Somying Tumwasorn, Thana Thongsricome, Maroot Kaewwongse, Rath Pitchyangkura, Piyaratana Tosukhowong, Natthaya Chuaypen, Thasinas Dissayabutra

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Weerapat AnegkamolMetabolic Disease in Gastrointestinal and Urinary System Research Unit, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Wirin BowonsomsaritMetabolic Disease in Gastrointestinal and Urinary System Research Unit, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Mana TaweevisitDepartment of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Somying TumwasornDepartment of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Thana ThongsricomeDepartment of Physiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Maroot KaewwongseDivision of Physiology, School of Medical Sciences, University of Phayao, Phayao, 56000, Thailand.
Rath PitchyangkuraDepartment of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand.
Piyaratana TosukhowongMetabolic Disease in Gastrointestinal and Urinary System Research Unit, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Natthaya ChuaypenMetabolic Disease in Gastrointestinal and Urinary System Research Unit, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Thasinas DissayabutraMetabolic Disease in Gastrointestinal and Urinary System Research Unit, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. thasinas@chula.md.

Funding

Fundamental Fund, Chulalongkorn University HEA663000050Program Management Unit for Human Resources and Institutional Development, Research, and Innovation (PMU-B) B36G660010Rachadapiseksompode Fund, Chulalongkorn University GA65/33Thailand Research Fund RSA280077
6 · The paper itself

Abstract

Hyperphosphatemia and secondary hyperparathyroidism (SHPT) are the common complications found in CKD that lead to severe complications including mineral bone disease (MBD), vascular calcification (VC), and cardiovascular mortality. To mitigate hyperphosphatemia, SHPT and uremic toxemia, we supplemented cisplatin-induced CKD rats with a synbiotic composed of Lactobacillus salivarius LBR228, Bifidobacterium longum BFS309, fructo-oligosaccharide and chitosan oligosaccharide, with Lactobacillus casei as a standard probiotic control. After the 12 weeks experiment, rats supplemented with the synbiotic had lower serum phosphate, calcium-phosphorus product, serum parathyroid hormone, and indoxyl sulfate levels than untreated rats. The expression of type 1 RNA and protein expression were increased in rats treated with the synbiotics. Our result showed that synbiotic treatment alleviates hyperphosphatemia and SHPT, which are the main risks of MBD and VC. The mode of the synbiotic action is hypothesized to associate with the improvement of the tight junction and gut barrier, leading to the suppression of intestinal paracellular phosphate transport. This study demonstrated the beneficial effects of synbiotic treatment in the control of serum phosphate and parathyroid hormone in an animal model with CKD.

Indexed as

Hyperparathyroidism, SecondaryHyperphosphatemiaRenal Insufficiency, ChronicSynbioticsAnimalsDisease Models, AnimalMaleOligosaccharidesParathyroid HormonePhosphatesRatsOligosaccharidesParathyroid HormonePhosphatesChronic kidney diseaseHyperparathyroidismParacellular transportPhosphateSynbioticsTight junction

Identifiers

PMID40032932
PMCPMC11876653

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.